Acasti Pharma Inc. (TSXV: ACST) is one of this year’s TSX Venture 50 companies — the company is a biopharmaceutical company operating in Canada.
Acasti Pharma focuses on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. The key product candidate of the company, CaPre is developed for the treatment of severe Hypertriglyceridemia.
The 2019 TSX Venture 50 is a ranking of top performers on the TSX Venture Exchange over the last year. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.
For the full 2019 TSX Venture 50 ranking, methodology and profile videos of companies included in the ranking, visit: www.tsx.com/venture50